低分子抑瘤物净化白血病细胞的实验研究及临床应用

胎儿肝脏中存在一类小分子量（分子量〈１０ｋＤ）的肿瘤抑制物,其在体外对ＨＬ－６０等多种白血病细胞系具有明显的选择性抑制作用,对急性白血病患者骨髓的白血病祖细胞也具有这种选择性抑制效果;分离纯化获得两种天然低分子抑瘤物（７－ＫＣ和７－β－ＨＣ）和一种外源性低分子抑瘤物（ＤＢＰ）,研究证实其抑制白血病细胞生长的作用机制是诱导白血病细胞凋亡;将其应用于白血病及恶性淋巴瘤自体骨髓移植时的体外净化,完成１２     

脑肿瘤抑制因子的功能研究

本文证明了胎脑组织中存在一类可以抑制人白血病细胞系的生长的低分子天然抑癌物．这种抑瘤物抑制活性分布在小于１０ｋＤａ组分,经Ｓｅｐｈａｄｅｘ－Ｇ２５凝胶过滤可分离为单一组分,且具有广谱的抗肿瘤效应．体外可抑制人白血病、肝癌、胃癌细胞系和小鼠粒、单核和淋巴系白血病细胞,而对人骨髓ＣＦＵ－ＧＭ和小鼠骨髓ＣＦＵ—ＧＭ的抑制作用较弱。     

新生牛肝中低分子抑瘤物影响白血病细胞生长的实验研究

新生牛肝经匀浆、离心和分级超滤后,得到分子量≤1.0kDa的、耐热的成分——新生牛肝抑瘤物(new-bom calfliver suppressor,BLS-1)。对BLS-1的生物学活性进行了检测,结果表明在体外液体和半固体琼脂培养条件下,它对人和小鼠白血病细胞系(如HL-60、L833 和 P388 等)的生长均有明显的抑制作用,并存在着一定的量效关系;与同样条件下BLS-1对人和小鼠正常粒-巨噬系祖细胞的抑制作用相比较,BLS-1对白血病细胞生长的抑制作用具有较强的选择性。进一步观察了BLS-1对5例急性非淋巴细胞白血病病人骨髓的原代白血病细胞集落(leukemic blast progenitor,L-CFU)生成的影响,结果表明,当BLS-1的浓度达到500μg/ml时,L-CFU的生成受到明显抑制。上述研究结果提示,在新生牛肝中可能存在类似于人胎儿肝脏中的一类低分子天然抑瘤物。     

人胚胎脑组织中低分子肿瘤抑制物的实验研究

人胚胎脑组织提取液可以抑制人白血病细胞系的生长。分析表明:肿瘤抑制活性主要分布在小于10kDa组分,经Sephadex-G25凝胶过滤可初步分离为单一组分。这种低分子肿瘤抑制物具有广谱的抗肿瘤效应,在体外可以抑制人白血病、肝癌、胃癌细胞系和小鼠粒、单核和淋巴系白血病细胞,但对人骨髓CFU-GM和小鼠骨髓CFU-GM的抑制作用较弱,说明人胎脑低分子肿瘤抑制物对肿瘤细胞具有一定的选择性抑制作用。     

新生牛肝中的低分子量抑瘤物对白血病干细胞影响的初步研究

新生牛肝中的低分子量抑瘤物对白血病干细胞影响的初步研究王福生,吴祖泽（北京军事医学科学院放射医学研究所１００８５０）近来,我们报道了新生牛肝中存在着一类天然低分子量的肿瘤抑制物（ＢＬＳ）,后者对体外培养的白血病细胞（系）及原代白血病祖细胞（Ｌ－ＣＦＵ...     

人胎肝中低分子抑瘤物的分离纯化、结构鉴定及其对肿瘤细胞生长的选择性抑制

在胎儿组织中存在一类低分子肿瘤抑制物,胎肝细胞的甲醇－丙酮提取物中保留有大部分抑瘤活性,用体外液体培养条件下对人急性粒系白血病细胞系（HL－60）的抑制作用为指标,跟踪指导分离过程,提取物经反相C18中压液相色谱,Sephadex LH-20凝胶色谱及氨基键合相高效液相色谱分离得到一纯活性物质。经NMR和MS鉴定为7－酮基胆固醇（7－ketocholesterol,7-KC)。体外琼脂培养条件下7－KC对小鼠WEHI－3和S－180细胞较对正常小鼠骨髓粒－巨噬系祖细胞有更强的抑制增殖及集落生成作用,7－KC对HL－60细胞增殖较对正常人骨髓CFU－GM有更强的抑制作用。     

人胎肝中低分子抑瘤物的分离纯化、结构鉴定及其对肿瘤细胞生长的选择性抑制作用

在胎儿组织中存在一类低分子肿瘤抑制物。胎肝细胞的甲醇－丙酮提取物中保留有大部分抑瘤活性。用体外液体培养条件下对人急性粒系白血病细胞系（ＨＬ－６０）的抑制作用为指标,跟踪指导分离过程。提取物经反相Ｃ１８中压液相色谱、ＳｅｐｈａｄｅｘＬＨ－２０凝胶色谱及氨基键合相高效液相色谱分离得到一纯活性物质,经ＮＭＲ和ＭＳ鉴定为７－酮基胆固醇（７－ｋｅｔｏｃｂｌｅｓｔｅｒｏｌ,７－ＫＣ）。体外琼脂培养条件下７－ＫＣ对小鼠ＷＥＨ１－３和Ｓ－１８０细胞较对正常小鼠骨髓粒一巨噬系祖细胞有更强的抑制增殖及集落生成作用。７－ＫＣ对ＨＬ－６０细胞增殖较对正常人骨髓ＣＦＵ－ＧＭ有更强的抑制作用。     

靶向CD123抗原嵌合受体T细胞治疗急性髓系白血病的研究

急性髓系白血病(AML)是一种预后较差的血液系统恶性肿瘤,迫切需要新的治疗手段。随着嵌合抗原受体(CAR)T细胞(CAR-T)技术的发展并在B细胞肿瘤中取得显著疗效,人们把目光投入更多的实体瘤与血液肿瘤靶点中。CD123分子是CAR-T治疗AML的潜在靶点,抗CD123 CAR-T具有靶向清除白血病干细胞(LSCs)及原始细胞的能力。本研究总结了目前在靶向CD123 CAR-T治疗急性髓系白血病目前的研究进展。     

20例低增生性急性白血病治疗的临床分析

低增生性急性白血病（HAL）是一种特殊类型急性白血病,骨髓中原始细胞数量增多而增生低下的急性白血病,病情重,化疗风险高,预后差。现对我院收治的20例低增生性急性白血病治疗的临床资料进行分析。     

白血病干细胞自我更新信号通路相关基因表达与白血病复发

除骨髓移植外,以化疗为主的急性白血病治愈率很低,尤其因耐药复发的难治性急性白血病不能治愈的原因是患者体内存在一群具有自我更新能力的白血病干细胞。虽然这些细胞数量极少,但可自我更新,具有很强的增殖潜能,在白血病发生和复发过程中起着关键性作用。白血病干细胞的存在和增殖受细胞表面分子、细胞调控信号通路、细胞自我更新信号通路与骨髓微环境等多因素影响,其中,细胞自我更新信号通路及其相关基因表达在维系白血病干细胞生物学特征方面发挥着重要作用     

Transforming growth factor beta: possible roles in the regulation of normal and leukemic hematopoietic cell growth

We have recently demonstrated that transforming growth factor (TGF)-beta 1 and TGF-beta 2 are potent inhibitors of the growth and differentiation of murine and human hematopoietic cells. The proliferation of primary unfractionated murine bone marrow by interleukin-3 (IL-3) and human bone marrow by IL-3 or granulocyte/macrophage colony-stimulating factor (GM-CSF) was inhibited by TGF-beta 1 and TGF-beta 2, while the proliferation of murine bone marrow by GM-CSF or murine and human marrow with G-CSF was not inhibited. Mouse and human hematopoietic colony formation was differentially affected by TGF-beta 1. In particular, CFU-GM, CFU-GEMM, BFU-E, and HPP-CFC, the most immature colonies, were inhibited by TGF-beta 1, whereas the more differentiated unipotent CFU-G, CFU-M, and CFU-E were not affected. TGF-beta 1 inhibited IL-3-induced growth of murine leukemic cell lines within 24 h, after which the cells were still viable. Subsequent removal of the TGF-beta 1 results in the resumption of normal growth. TGF-beta 1 inhibited the growth of factor-dependent NFS-60 cells in a dose-dependent manner in response to IL-3, GM-CSF, G-CSF, CSF-1, IL-4, or IL-6. TGF-beta 1 inhibited the growth of a variety of murine and human myeloid leukemias, while erythroid and macrophage leukemias were insensitive. Lymphoid leukemias, whose normal cellular counterparts were markedly inhibited by TGF-beta, were also resistant to TGF-beta 1 inhibition. These leukemic cells have no detectable TGF-beta 1 receptors on their cell surface. Last, TGF-beta 1 directly inhibited the growth of isolated Thy-1-positive progenitor cells. Thus, TGF-beta may be an important modulator of normal and leukemic hematopoietic cell growth.     

Modeling Chemotherapy Resistant Leukemia In Vitro

It is well established that the bone marrow microenvironment provides a unique site of sanctuary for hematopoietic diseases that both initiate and progress in this site. The model presented in the current report utilizes human primary bone marrow stromal cells and osteoblasts as two representative cell types from the marrow niche that influence tumor cell phenotype. The in vitro co-culture conditions described for human leukemic cells with these primary niche components support the generation of a chemoresistant subpopulation of tumor cells that can be efficiently recovered from culture for analysis by diverse techniques. A strict feeding schedule to prevent nutrient fluxes followed by gel type 10 cross-linked dextran (G10) particles recovery of the population of tumor cells that have migrated beneath the adherent bone marrow stromal cells (BMSC) or osteoblasts (OB) generating a "phase dim" (PD) population of tumor cells, provides a consistent source of purified therapy resistant leukemic cells. This clinically relevant population of tumor cells can be evaluated by standard methods to investigate apoptotic, metabolic, and cell cycle regulatory pathways as well as providing a more rigorous target in which to test novel therapeutic strategies prior to pre-clinical investigations targeted at minimal residual disease.     

唾液酸对正常造血细胞及白血病细胞增殖分化的影响

本实验以测定细胞电泳率(EPM)反映细胞表面唾液酸相对含量。发现胎肝细胞电泳率明显高于成年骨髓细胞,经神经氨酸酶(NA)处理胎肝细胞、骨髓细胞、L_(801)急性白血病细胞和KCL-22慢性白血病细胞后,细胞EPM均明显下降。细胞集落数及细胞形态学检测表明,NA处理后,多向造血干细胞(CFU-S)增殖能力减弱,向粒系的分化增强;KCL-22细胞生成的集落数明显减少,成熟细胞的比例明显增加。     

Effects of rare earth compounds on growth and apoptosis of leukemic cell lines

To explore a new agent for inhibiting leukemic cells, we investigated the effects of rare earth compounds (lanthanum chloride and cerium chloride) on the growth and apoptosis of HL-60 and NB4 cells. The growth of HL-60 and NB4 cells was tested by 3-(4,5-dimethylthiazole-2-yl)-2,5-biphenyl tetrazolium bromide (MTT) colorimetric assay. The apoptosis was measured by light microscopy, flow cytometry, and terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate (dUTP) nick-end labeling (TUNEL) method. The effect of LaCl(3) on normal bone marrow hematopoietic progenitor cells was evaluated by colony-forming unit-granulocyte-macrophage (CFU-GM) assay. Under our experimental conditions, MTT assay showed that 48-h treatment with 1, 2, and 3 mM LaCl(3) or 48- and 72-h treatments with 1 mM LaCl(3) could significantly inhibit the growth of HL-60 cells. Treatment with 2 and 4 mM CeCl(3) for 72 h could significantly inhibit the growth of NB4 cells. Apoptosis could be detected on treatment with 2 mM LaCl(3) for 24 h in HL-60 cells by light microscopic morphology examination, flow cytometric analysis, and TUNEL method. Apoptosis could be also detected on treatment with 2 mM CeCl(3) for 72 h in NB4 cells. Treatment with 1 mM LaCl(3) could arrest the transitions from G0/G1 to S phase. The granulocyte-macrophage colony formation of normal bone marrow cells was not significantly inhibited at lower concentrations of LaCl(3) (0.5 to 2 mM). Our results indicate that at certain concentrations, the rare earth compounds may inhibit the growth of leukemic cells, induce them to apoptosis, and have no significant inhibitory effects on normal bone marrow hematopoietic progenitor cells (CFU-GM). The mechanism needs to be further investigated.     

Purification of a novel growth inhibitory factor for partially differentiated myeloid leukemic cells

A novel factor termed growth inhibitory (GI) factor, which specifically inhibits the growth of mouse monocytic leukemia cells including monocytic cell lines (Mm-A and J774.1) and other partially differentiated myeloid leukemic cells, has been purified from conditioned medium of some clones of mouse myeloblastic leukemia M1 cells. The procedure for purification of the GI factor included ammonium sulfate precipitation, CM-Sepharose CL-6B and Sephadex G-200 chromatographies, reverse-phase high-performance liquid chromatography on a C18 hydrophobic support, and high-performance liquid chromatography on a gel filtration column. The purified factor gave a single band of protein with a molecular weight of 25,000 on sodium dodecyl sulfate-polyacrylamide gel. A concentration of 8 X 10(-10) M GI factor was required for 50% inhibition of growth of Mm-A cells. On chromatofocusing, the GI activity was eluted with Polybuffer 96/acetic acid at pH 8.2-8.4. The purified GI factor markedly inhibited growth of mouse bone marrow cells stimulated by macrophage colony-stimulating factor. The GI factor appeared to be a unique cytokine unrelated to known cytokines such as the tumor necrosis factor, interferons, and oncostatin M.     

Antibodies to colony-stimulating factors block Lewis lung carcinoma cell stimulation of immune-suppressive bone marrow cells

Summary Progressive growth of metastatic Lewis lung carcinoma (LLC) tumors results in a concurrent stimulation of myelopoiesis and the appearance of immune-suppressive bone marrow cells. The present study has shown that normal bone marrow cells could be induced to become immune-suppressive by 3 days of culture with supernatants of cloned metastatic LLC-LN7 variant cells. The capacity of the LLC-LN7 supernatants to stimulate the appearance of suppressor cells was directly proportional to the concentration of supernatant used in the bone marrow culture. When adoptively transferred with a LLC-LN7 tumor inoculum, the supernatant-induced suppressor bone marrow cells increased the rate of appearance of palpable tumors and the frequency of tumor establishment. The LLC-LN7 supernatants containing suppressor-cell-inducing activity also had colony-stimulating factor (CSF) activity. The CSF activity produced by the LLC-LN7 cells could be diminished with neutralizing antibodies to either granulocyte/monocyte(GM-) CSF or to interleukin-3 (IL-3). Likewise, the suppressor-inducing activity in the LLC-LN7 supernatants was diminished by pretreatment with anti-GM-CSF or anti-IL-3. The combination of anti-GM-CSF and anti-IL-3 completely neutralized all suppressor-inducing activity produced by the LLC-LN7 cells. These results suggest that the secretion of IL-3 and GM-CSF by LLC-LN7 tumor cells is a mechanism by which the tumors stimulate myelopoiesis and induce normal bone marrow cells to become immune-suppressive. Bone marrow cells that are induced to become immune-suppressive by culture with LLC-LN7 supernatants can, in turn, facilitate the establishment of tumor in vivo.This study was supported by the Medical Research Services of the Veterans Administration and by grant CA-45080 from the National Institutes of Health